4.2 Article

Treatment Strategies and Clinical Trial Design in ADPKD

期刊

ADVANCES IN CHRONIC KIDNEY DISEASE
卷 17, 期 2, 页码 190-204

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ackd.2010.01.006

关键词

Polycystic kidney disease; ADPKD; Cyclic AMP; Vasopressin V2 receptor antagonist; Mammalian target of rapamycin; Somatostatin analogs; Consortium for radiologic imaging study of PKD

资金

  1. Otsuka
  2. Novartis
  3. Wyeth Pharmaceuticals

向作者/读者索取更多资源

More frequent utilization and continuous improvement of imaging techniques has enhanced appreciation of the high phenotypic variability of autosomal dominant polycystic kidney disease, improved understanding of its natural history, and facilitated the observation of its structural progression. At the same time, identification of the PKD1 and PKD2 genes has provided clues to how the disease develops when they (genetic mechanisms) and their encoded proteins (molecular mechanisms) are disrupted. Interventions designed to rectify downstream effects of these disruptions have been examined in animal models, and some are currently tested in clinical trials. Efforts are underway to determine whether interventions capable to slow down, stop, or reverse structural progression of the disease will also prevent decline of renal function and improve clinically significant outcomes. (C) 2010 by the National Kidney Foundation, Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据